Valor202020212022202320242025TTMGastos comerciales, generales y administrativos103.27 M135.9 M212.95 M189.74 M218.4 M246.98 M260.54 MInvestigación y desarrollo43.01 M69.07 M120.31 M106.89 M90.85 M80.28 M76.11 MBeneficio operativo-140.08 M-152.73 M-234.78 M-217.16 M-220.83 M-136.26 M-134.51 MTotal de ingresos no operativos1.32 M-930 K6.58 M13.7 M12.69 M10.46 M9.96 MGastos por intereses, netos de intereses capitalizados787 K367 K80 K5 00029 K——Ingresos no operativos, una vez deducidos los gastos por intereses712 K73 K7.59 M14.36 M15.31 M11.36 M10.16 MIngresos/gastos extraordinarios-182 K-1.37 M-1.09 M-667 K-2.65 M-903 K-339 KBeneficio antes de impuestos-139.55 M-154.03 M-228.27 M-203.47 M-208.17 M-76.95 M-75.71 MParticipación en los beneficios———————Impuestos382 K-1.93 M-10.41 M1.15 M560 K719 K875 KParticipación minoritaria———————Otros ingresos/gastos después de impuestos-152 K-67 K-3 000——-2.2 M-1.89 MBeneficio neto antes de actividades interrumpidas-139.93 M-152.1 M-217.86 M-204.62 M-208.73 M-77.67 M-76.58 MOperaciones suspendidas———————Beneficio neto-139.93 M-152.1 M-217.86 M-204.62 M-208.73 M-77.67 M-76.58 MAjuste por dilución———————Dividendos de las acciones preferentes———————Beneficio neto diluido atribuible a los accionistas-139.93 M-152.1 M-217.86 M-204.62 M-208.73 M-77.67 M-76.58 MBeneficio básico por acción——-4.04-3.6-3.6-1.3-1.27Beneficio por acción diluido——-4.04-3.6-3.6-1.3-1.27Número medio de acciones ordinarias——53.88 M56.88 M58.02 M59.81 M240.53 MAcciones diluidas——53.88 M56.88 M58.02 M59.81 M241.7 MEBITDA-133.4 M-142.98 M-218.26 M-187.85 M-189.4 M-111.41 M-109.85 MEBIT-140.08 M-152.73 M-234.78 M-217.16 M-220.83 M-136.26 M-134.51 MCosto de los ingresos61.41 M80.62 M119.33 M155.38 M179.63 M185.57 M189.42 MOtros costes de producción———————Amortización y depreciación (flujo de caja)6.68 M9.75 M16.51 M29.31 M31.43 M24.85 M24.67 M
Twist Bioscience Corporation
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
The company was represented by Leproust at a March 2021 tabletop exercise at the Munich Security Conference simulating an outbreak of weaponized monkeypox.
In May 2021, Twist Bioscience and Genome Project-Write launched a new CAD platform for whole genome design. The CAD will automate workflows to enable collaborative efforts critical for scale-up from designing plasmids to megabases across entire genomes.